Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FTRE
HOLDFortrea Holdings Inc. · Healthcare · United States · $1.8B · Avg Vol: $27M/d
COMPANY DESCRIPTION
Fortrea Holdings Inc. is a global contract research organization (CRO) providing clinical development, patient access, and post-approval services to pharmaceutical and biotechnology companies. Its extensive global footprint, deep scientific and therapeutic expertise, and integrated suite of services position it as a critical partner in accelerating drug development for biopharma clients. Fortrea is a significant independent CRO in the drug development ecosystem.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.8B | 2.8B | 2.7B | 2.7B | -1.4% | 2.7B | 2.6B | 2.7B | -0.4% |
| EPS | 2.11 | -0.04 | -3.67 | -10.81 | — | -4.80 | — | — | — |
| Shares | 88.8M | 88.8M | 89.7M | 93.1M | +4.8% | 94.6M | — | — | — |
| Debt | 63.4M | 1.7B | 1.2B | 1.1B | 160.1% | 1.1B | — | — | — |
| Equity | 3.3B | 1.7B | 1.4B | 563.5M | -44.8% | — | — | — | — |
| Op CF | 82.7M | 168.4M | 262.8M | 113.5M | 11.1% | 220.7M | — | — | — |
| Inv CF | -54.0M | -31.8M | 251.6M | 14.4M | — | — | — | — | — |
| Fin CF | -6.3M | -140.8M | -497.8M | -76.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FTRE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FTRE | Fortrea Holdings Inc.(you) | $1.8B | 58 | HOLD |
| VCEL | Vericel Corporation | $2.3B | 64 | HOLD |
| URGN | UroGen Pharma Ltd. | $2.0B | 47 | HOLD |
| ANAB | AnaptysBio, Inc. | $1.6B | 47 | HOLD |
| TBPH | Theravance Biopharma, Inc. | $874M | 54 | HOLD |
| ACAD | ACADIA Pharmaceuticals Inc. | $4.3B | 60 | HOLD |
| MRVI | Maravai LifeSciences Holdings, Inc. | $2.5B | 42 | HOLD |
| ADMA | ADMA Biologics, Inc. | $1.9B | 35 | SELL |
| SLS | SELLAS Life Sciences Group, Inc. | $2.2B | 38 | HOLD |
| SRPT | Sarepta Therapeutics, Inc. | $1.7B | 36 | HOLD |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%